FDA近期对细胞与基因治疗领域人员和政策的调整对于中国企业在美国开展这方面临床研究的影响？
临床研究

What impact do recent FDA personnel and policy changes in the cell and gene therapy field have on Chinese enterprises conducting clinical studies in the U.S. in this area?

2025-07-16 16:21 识林-树苗     
举报
 评论 回答
0个回答